Cme Group Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cme Group Inc (CME) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cme Group Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 6,773M vs 208,217M combined for tracked competitors (3.2% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.8% annualized vs trailing 12 months), vs accelerating (+3.4%) for its tracked peer group.
- Growth: Cme Group Inc generated 0.8% revenue growth year over year in Q2 2026, vs 15.0% for its tracked competitors combined.
- Profitability: Its 61.1% net margin compares with 6.5% for the peer group.
- Scale: Cme Group Inc ranks #7 of 91 companies by market capitalization in the Investment Services industry, holding 4.2% of industry market cap.
- Peer revenue share: Cme Group Inc accounted for 3.1% of combined revenue among its tracked peer group, down from 3.5% a year earlier.
- Peer differentiation: Revenue per employee of $1.75M compares with $1.10M for the peer group (1.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CME Sales vs. its Competitors, Q2 2026
Cme Group Inc reported revenue growth of 0.84 % year on year in Q2 2026, below its competitors' combined revenue growth of 14.95 %.
With a net margin of 61.06 %, Cme Group Inc achieved higher profitability than its competitors (6.47 %).
Cme Group Inc generated 3.07 % of the combined sales of its peer group, down from 3.49 % a year earlier.
Cme Group Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cme Group Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cme Group Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cme Group Inc's competitor groups requires a Commercial License.
For context: the Investment Services industry grew revenue -2.0% year over year, combined, vs 0.8% for Cme Group Inc. Cme Group Inc's share of combined industry revenue moved from 0.66% to 0.68%, a gain of 0.02 percentage points.
Cme Group Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cme Group Inc | Yes | Yes | No | Yes |
| Competitors combined (14) | ||||
| High-Confidence Competitors (1) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 87.50 % (7 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CME Stock Performance relative to its Competitors
CME Stock Performance relative to High-Confidence Competitors
CME Stock Performance relative to Similar-Size Competitors
CME Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Financial Institutions Inc | 282.9% | Outperformed |
| 2 | Bgc Group Inc | 282.9% | Outperformed |
| 3 | Stonex Group Inc | 282.9% | Outperformed |
| 4 | Nasdaq Inc | 282.9% | Outperformed |
| 5 | Cboe Global Markets Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cme Group Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cme Group Inc's Comment on Competition and Industry Peers
Competition in our Derivatives Business
We believe competition in the derivatives and securities business is based on
a number of factors, including, among others:
reputation;
efficient and secure settlement, clearing and support services;
depth and liquidity of markets;
breadth of product offerings and rate and quality of new product development;
ability to position and expand upon existing products to address changing market
needs;
transparency, reliability and anonymity in transaction processing;
regulatory environment;
connectivity, accessibility and distribution;
technological capability and innovation; and
transaction costs.
We believe that we compete favorably with respect to these factors. Our deep,
liquid markets; diverse product offerings; rate and quality of new product development;
and efficient, secure settlement, clearing and support services, distinguish
us from our competitors. We believe that in order to maintain our competitive
position, we must continue to expand globally; develop new and innovative products;
enhance our technology infrastructure, including its reliability and functionality;
maintain liquidity and low transaction costs, and implement customer protections
designed to ensure the integrity of our market and the confidence of our customers.
Our competitors include, among other entities, exchanges such as IntercontinentalExchange
Group, Inc. (ICE Group); the Hong Kong Exchanges and Clearing Limited; and Deutsche
Börse AG. In addition, competition in our industry is dynamic and recent
developments and alliances may result in a growing number of well-capitalized
trading service providers that compete with all or a portion of our business.
We also face competition from the over-the-counter marketplace, spot markets,
securities exchanges and other venues offering "look-alike" or close
substitutes for our listed contracts.
In addition, the development of swap execution facilities and the mandated trading
and/or clearing requirement for certain products may lead to the creation of
platforms that promote competitive substitutes for our privately negotiated
and exchange-traded products.
Competition in our Transaction Processing Business
In addition, we face a number of competitors in our transaction processing and
other business services. In the past few years, there has been increased competition
in the provision of clearing services and we expect competition to continue
to increase in connection with the continued implementation of and compliance
with Dodd-Frank.
Our competitors in the clearing services space include, among others, companies
such as ICE Group, LCH.SwapClear and Deutsche Börse AG. In light of Dodd-Franks
clearing mandate and other reforms of the financial services industry, we believe
that other exchanges and infrastructure providers also may undertake to provide
clearing services.
We believe competition in the transaction processing and business services market
is based on, among other things, the fees charged for the services provided;
quality and reliability of the services; creditworthiness of the clearing house;
timely delivery of the services; reputation; offering breadth; confidentiality
of positions and information security protective measures; and the value of
providing customers with capital efficiencies.
Competition in our Market Data Business
Technology companies, market data and information vendors and front-end software
vendors also represent actual and potential competitors because they have their
own substantial market data distribution capabilities which could serve as alternative
means for receiving open market data feeds instead of connecting directly to
our exchange. Distributors and consumers of our market data may also use our
market data as an input into a product that competes against one of our traded
or cleared products. Although we may receive license fees for such products,
such fees may not exceed the impact of any loss in trading volume of our comparable
product.
Publicly Traded Peers of Cme Group Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cme Group Inc | 95,103.87 | 6,772.60 |
| Intercontinental Exchange Inc | 87,311.16 | 13,505.00 |
| Moody s Corporation | 80,283.96 | 8,183.00 |
| Nasdaq Inc | 53,096.00 | 8,751.00 |
| Cboe Global Markets Inc | 26,566.97 | 5,061.30 |
| Tradeweb Markets Inc | 21,443.37 | 2,263.53 |
| SUBTOTAL | 432,695.48 | 219,167.05 |
Sign in to see all competitors of Cme Group Inc .
Sources: Cme Group Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cme Group Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cme Group Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| LCH Group | Named by the company | 85% |
| Hong Kong Exchanges and Clearing Limited | Named by the company | 85% |
| Depository Trust & Clearing Corporation | Named by the company | 85% |
| Options Clearing Corporation | Named by the company | 85% |
| Intercontinental Exchange, Inc. (ICE) | Named by the company | 85% |
| Deutsche Börse AG | Named by the company | 85% |
| Bgc Group Inc | Named by the company | 85% |
| Bank Bradesco | Named by the company | 85% |
| Tradeweb Markets Inc | Named by the company | 85% |
| Financial Institutions Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Cme Group Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Cme Group Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Intercontinental Exchange Inc | Exchanges 66.94 % |
| Moody s Corporation | Rating Revenue 57.12 % |
| Nasdaq Inc | Market Services 54.19 % |
| Cboe Global Markets Inc | Options 51.50 % |
| Tradeweb Markets Inc | Reportable 97.25 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cme Group Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cme Group Inc | 95,104 | 1,747,768 | 1,103,071 |
| Intercontinental Exchange Inc | 87,311 | 1,051,464 | 319,215 |
| Moody s Corporation | 80,284 | 509,020 | 174,048 |
| Nasdaq Inc | 53,096 | 340,784 | 76,561 |
| Cboe Global Markets Inc | 26,567 | 3,047,140 | 811,981 |
| Tradeweb Markets Inc | 21,443 | 1,442,656 | 648,519 |
| PEERS TOTAL | 337,592 | 1,097,067 | 92,993 |
Cme Group Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Moody s Corporation | United States 55.74 % |
| Nasdaq Inc | United States 75.24 % |
| Tradeweb Markets Inc | Non-US 43.15 % |
| News Corporation | United States and Canada 48.38 % |
| Stonex Group Inc | Middle East and Asia 90.47 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cme Group Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 88 companies in Cme Group Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cme Group Inc ranks #7 of 88 companies by market capitalization in its industry, holding 4.17 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 606, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Morgan Stanley | 303,821 | 13.32 % |
| 2 | The Goldman Sachs Group Inc | 279,374 | 12.24 % |
| 3 | Blackrock Inc | 176,379 | 7.73 % |
| 4 | Schwab Charles Corp | 170,944 | 7.49 % |
| 5 | Futu Holdings Ltd | 1,234 | 5.2% |
| 6 | Robinhood Markets Inc | 1,234 | 5.2% |
| 7 | Cme Group Inc | 95,104 | 4.17 % |
| 8 | Blackstone Inc | 1,234 | 5.2% |
| 9 | Kkr and co inc | 1,234 | 5.2% |
| 10 | Intercontinental Exchange Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Cme Group Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Cme Group Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 2 | The Goldman Sachs Group Inc | 279,374 | 16.49 % |
| 3 | Blackrock Inc | 176,379 | -5.91 % |
| 4 | Schwab Charles Corp | 170,944 | 3.82 % |
| 5 | Futu Holdings Ltd | 126,960 | -37.46 % |
| 6 | Robinhood Markets Inc | 1,234 | 12.3% |
| 7 | Cme Group Inc | 95,104 | -0.47 % |
| 8 | Blackstone Inc | 1,234 | 12.3% |
| 9 | Kkr and co inc | 1,234 | 12.3% |
| 10 | Intercontinental Exchange Inc | 1,234 | 12.3% |
| 11 | Apollo Global Management Inc | 1,234 | 12.3% |
| 12 | Brookfield Asset Management Ltd | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Cme Group Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Cme Group Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Investment Services industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (78 companies). See the full Investment Services industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 61.67 % (avg) | -61.7 pp |
| Operating Margin | 69.73 % | industry median | +33.6 pp |
| EBITDA Margin | 83.68 % | 19.52 % (avg) | +64.2 pp |
| Capital Intensity (Capex / Revenue) | 1.42 % | 2.93 % (avg) | -1.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Cme Group Inc's Valuation vs Competitive Position
Valuation multiples vs the Investment Services industry average (78 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Investment Services industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 23.5x | 23.9x | -0.4x |
| EV / EBITDA | 17.7x | 12.8x | +4.9x |
| P/B | 3.6x | 3.0x | +0.6x |
| Return on Equity | 15.54 % | industry aggregate | -0.30 % |
| Return on Invested Capital | 3.22 % | 8.46 % (avg) | -5.24 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cme Group Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 18.24 % | 12.96 % | 0.32 % | -3.97 % | 7.03 % | 11.15 % | 9.88 % | 6.37 % |
| Operating Margin | -32.53 % | 53.16 % | 54.01 % | 60.39 % | 73.82 % | 66.90 % | 68.95 % | 69.67 % |
| Return on Invested Capital | -2.48 % | 4.07 % | 4.15 % | 4.28 % | 5.69 % | 5.77 % | 6.66 % | 2.64 % |
| P/E | 32.5x | 34.7x | 30.4x | 30.9x | 23.5x | 23.7x | 23.8x | 24.4x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cme Group Inc's Strategic Group Map
Every company in Cme Group Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Cme Group Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Cme Group Inc's BCG Growth-Share Matrix
Relative market share (vs Cme Group Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Cme Group Inc falls in the Dog quadrant: relative market share of 0.31x vs its largest competitor, in an industry growing revenue 9.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Cme Group Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 606 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.42 % vs industry average 2.93 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Cme Group Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Cme Group Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Cme Group Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Cme Group Inc falls in the Medium attractiveness / Medium strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Cme Group Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 33.6 points above the industry median.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.31x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cme Group Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cme Group Inc | 0.02 | 1.00 | 0.12 |
| Intercontinental Exchange Inc | 0.02 | 0.95 | 0.68 |
| Moody s Corporation | 0.60 | 1.44 | 1.95 |
| Nasdaq Inc | 0.11 | 1.11 | 0.74 |
| Cboe Global Markets Inc | 0.71 | 1.59 | 0.31 |
| Tradeweb Markets Inc | 3.52 | 3.11 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cme Group Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cme Group Inc | Q2 2026 | +0.8 % | +2.9 % |
| Intercontinental Exchange Inc | Q2 2026 | +9.7 % | +12.7 % |
| Moody s Corporation | Q2 2026 | +15.1 % | +51.8 % |
| Nasdaq Inc | Q2 2026 | +21.1 % | +12.2 % |
| Cboe Global Markets Inc | Q2 2026 | +23.0 % | +51.0 % |
| Tradeweb Markets Inc | Q2 2026 | +5.9 % | +17.8 % |
| PEERS TOTAL | +14.3 % | +18.3 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cme Group Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cme Group Inc | Q2 2026 | - | +28.3 % |
| Intercontinental Exchange Inc | Q2 2026 | - | +56.9 % |
| Moody s Corporation | Q2 2026 | +5.9 % | +21.3 % |
| Nasdaq Inc | Q2 2026 | +29.8 % | +30.5 % |
| Cboe Global Markets Inc | Q2 2026 | +21.4 % | +63.1 % |
| Tradeweb Markets Inc | Q2 2026 | - | +23.4 % |
Cme Group Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cme Group Inc | 2.19% | 3.58% | 15.54% |
| Intercontinental Exchange Inc | 2.60% | 3.16% | 14.04% |
| Moody s Corporation | 18.45% | 21.89% | 76.52% |
| Nasdaq Inc | 6.76% | 7.29% | 16.28% |
| Cboe Global Markets Inc | 13.47% | 18.06% | 25.66% |
| Tradeweb Markets Inc | 12.43% | 11.90% | 14.15% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cme Group Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cme Group Inc | 22.33 | 14.04 |
| Intercontinental Exchange Inc | 21.82 | 6.47 |
| Moody s Corporation | 29.21 | 9.81 |
| Nasdaq Inc | 27.28 | 6.07 |
| Cboe Global Markets Inc | 19.74 | 5.25 |
| Tradeweb Markets Inc | 24.08 | 9.47 |
| PEERS AVERAGE | 19.42 | 1.97 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.